Dexcom (DXCM) Stock Price
Dexcom Price
Revenue has compounded at 49.8% per year over the past 19 years to 4.66 B USD. Earnings per share have grown at 40.5% per year over the last 6 years. Dexcom's net margin stands at 17.9%, up from 8.9% several years earlier. Analysts set a median price target of 86.10 USD, implying 2.4% below the current price. Of 37 analysts, 31 rate the stock a buy — an overall Buy consensus. The stock trades about 61% above its 52-week low.
Dexcom stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Dexcom over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Dexcom stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Dexcom's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Dexcom Price |
|---|---|
| 9/4/2026 | 88.18 USD |
| 9/3/2026 | 89.71 USD |
| 9/2/2026 | 89.69 USD |
| 9/1/2026 | 90.14 USD |
| 8/31/2026 | 90.31 USD |
| 8/28/2026 | 90.55 USD |
| 8/27/2026 | 90.38 USD |
| 8/26/2026 | 88.96 USD |
| 8/25/2026 | 89.16 USD |
| 8/24/2026 | 92.24 USD |
| 8/21/2026 | 92.34 USD |
| 8/20/2026 | 90.22 USD |
| 8/19/2026 | 89.83 USD |
| 8/18/2026 | 90.99 USD |
| 8/14/2026 | 89.75 USD |
| 8/13/2026 | 91.48 USD |
| 8/12/2026 | 90.80 USD |
| 8/11/2026 | 89.53 USD |
| 8/10/2026 | 87.63 USD |
| 8/7/2026 | 84.75 USD |
| 8/6/2026 | 83.02 USD |
| 8/5/2026 | 82.63 USD |
| 8/4/2026 | 86.79 USD |
| 8/3/2026 | 87.31 USD |
| 7/31/2026 | 83.45 USD |
| 7/30/2026 | 74.54 USD |
| 7/29/2026 | 75.87 USD |
| 7/27/2026 | 73.85 USD |
| 7/23/2026 | 70.48 USD |
| 7/22/2026 | 71.43 USD |
Dexcom Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Dexcom Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.40 | 0.57 | 0.72 | 1.03 | 1.48 | 1.93 | 2.45 | 2.91 | 3.62 | 4.03 | 4.66 | 5.23 | 5.80 | 6.45 | 7.20 | 7.98 |
| 55.21 | 42.54 | 25.31 | 43.59 | 43.16 | 30.49 | 27.10 | 18.83 | 24.51 | 11.35 | 15.60 | 12.18 | 10.82 | 11.30 | 11.58 | 10.85 |
| 69.15 | 65.97 | 68.52 | 64.31 | 63.08 | 66.46 | 68.63 | 64.73 | 63.17 | 60.45 | 60.08 | 60.08 | 60.08 | 60.08 | 60.08 | 60.08 |
| 0.28 | 0.38 | 0.49 | 0.66 | 0.93 | 1.28 | 1.68 | 1.88 | 2.29 | 2.44 | 2.80 | 3.14 | 3.48 | 3.88 | 4.32 | 4.79 |
| -0.06 | -0.06 | -0.04 | -0.19 | 0.14 | 0.30 | 0.27 | 0.39 | 0.60 | 0.60 | 0.91 | 1.27 | 1.47 | 1.74 | 2.18 | 2.54 |
| -14.18 | -11.17 | -5.43 | -18.04 | 9.62 | 15.52 | 10.83 | 13.44 | 16.48 | 14.88 | 19.54 | 24.32 | 25.43 | 26.93 | 30.30 | 31.85 |
| -0.06 | -0.07 | -0.05 | -0.13 | 0.10 | 0.49 | 0.22 | 0.34 | 0.54 | 0.58 | 0.84 | 1.04 | 1.22 | 1.45 | 1.69 | 1.97 |
| 159.09 | 14.04 | -23.08 | 154.00 | -179.53 | 388.12 | -56.19 | 57.87 | 58.65 | 6.47 | 45.14 | 24.40 | 17.02 | 19.15 | 16.48 | 16.64 |
| 340.00 | 338.40 | 347.60 | 354.80 | 371.20 | 390.00 | 388.00 | 425.90 | 415.90 | 406.70 | 398.90 | 398.90 | 398.90 | 398.90 | 398.90 | 398.90 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Dexcom generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Dexcom retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Dexcom's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Dexcom has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Dexcom's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Dexcom stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Dexcom Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Dexcom business model & stock analysis
Dexcom Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Dexcom Segments
Dexcom Revenue by Region
3 Years
5 Years
Max
Details
Dexcom Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Dexcom historical P/E ratio, EBIT multiple, and P/S ratio
Dexcom annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Dexcom shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Dexcom stock splits
Current Dexcom forecasts and price targets in September 2026
Analyst Price Targets 2026Dexcom Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/4/2026 | Maintained | Buy | – | |
| 8/3/2026 | Maintained | Buy | 64 | |
| 7/31/2026 | Maintained | Overweight | 55 | |
| 7/31/2026 | Maintained | Buy | – | |
| 7/31/2026 | Maintained | Buy | 56 | |
| 7/31/2026 | Maintained | Outperform | 49 | |
| 7/31/2026 | Maintained | Overweight | 50 | |
| 7/31/2026 | Maintained | Outperform | 31 | |
| 7/31/2026 | Maintained | Neutral | 59 | |
| 7/31/2026 | Maintained | Buy | 48 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Dexcom Earnings Calls
Dexcom Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 7/30/2026 | 0.62USD | - | 1.32 BUSD | - | 2026 Q2 |
| 4/30/2026 | 0.48USD | - | 1.20 BUSD | - | 2026 Q1 |
| 2/12/2026 | 0.66USD | - | 1.27 BUSD | - | 2025 Q4 |
| 4/25/2024 | 0.30USD | - | 937.20 MUSD | - | 2024 Q1 |
| 2/7/2024 | 0.43USD | - | 1.03 BUSD | - | 2023 Q4 |
| 7/26/2023 | 0.25USD | - | 845.51 MUSD | - | 2023 Q2 |
| 4/26/2023 | 0.19USD | - | 755.90 MUSD | - | 2023 Q1 |
| 2/8/2023 | 0.28USD | - | 820.59 MUSD | - | 2022 Q4 |
| 10/27/2022 | 0.25USD | - | 762.19 MUSD | - | 2022 Q3 |
| 7/28/2022 | 0.19USD | - | 709.03 MUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Dexcom stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Dexcom shareholder structure
| % | Name |
|---|---|
9.99035% | |
6.41530% | |
4.92794% | |
4.59844% | |
3.99967% | |
3.31358% |
Dexcom Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
11.00% | SEC ↗ | |
10.74% | SEC ↗ | |
10.40% | SEC ↗ | |
9.90% | SEC ↗ | |
8.70% | SEC ↗ | |
8.30% | SEC ↗ | |
8.10% | SEC ↗ | |
8.10% | SEC ↗ | |
8.10% | SEC ↗ | |
7.60% | SEC ↗ |
Dexcom Executives and Management Board
13 members · avg. age 57 · 31 % women
Mr. Jacob Leach (47)
President, Interim Principal Executive Officer, Chief Operating Officer
5.92 M USD
Management
Mr. Jereme Sylvain (45)
Chief Financial Officer, Executive Vice President
Mr. Michael Brown (55)
Executive Vice President, Chief Legal Officer
Ms. Sadie Stern (50)
Chief Human Resources Officer, Executive Vice President
Mr. Sean Christensen
Vice President - Finance and Investor Relations · since 2023
Board of Directors
Mr. Mark Foletta (64)
Interim Independent Chairman of the Board
Mr. Richard Collins (68)
Independent Director
Ms. Rimma Driscoll (52)
Independent Director
Mr. Nicholas Augustinos (66)
Independent Director
Ms. Bridgette Heller (64)
Independent Director
Mr. Steven Altman (63)
Independent Director
Dexcom Supply Chain
Dexcom Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.89 | 0.80 | 0.82 | ||
| 2 | 0.78 | 0.81 | 0.69 | ||
| 3 | 0.83 | 0.85 | 0.68 | ||
| 4 | 0.71 | 0.64 | 0.65 | ||
| 5 | Novo Nordisk B | 0.10 | 0.11 | 0.63 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.23 | -0.54 | -0.34 | ||
| 2 | 0.84 | 0.53 | -0.31 | ||
| 3 | Rockley Photonics | 0.77 | 0.32 | -0.30 | |
| 4 | -0.50 | -0.49 | 0.21 | ||
| 5 | -0.39 | -0.46 | 0.28 |
Frequently asked questions about Dexcom
Dexcom Inc's business model revolves around the development and distribution of continuous glucose monitoring systems. The company specializes in providing innovative medical devices and software solutions to monitor glucose levels in individuals with diabetes. Dexcom's products enable patients and healthcare professionals to make accurate, real-time glucose management decisions, contributing to improved diabetes management and overall patient outcomes. Dexcom Inc's commitment to technological advancements and medical innovation has positioned the company as a market leader in the field of continuous glucose monitoring.
Dexcom Inc is primarily active in the healthcare and medical devices industry.
The main competitors of Dexcom Inc in the market include Abbott Laboratories, Medtronic, and Tandem Diabetes Care.
Dexcom Inc is a leading medical device manufacturing company based in San Diego, California. Established in 1999, Dexcom has revolutionized diabetes management with their continuous glucose monitoring (CGM) systems. Dexcom's advanced CGM systems provide real-time glucose readings, helping diabetes patients effectively manage their condition. Over the years, the company has pioneered innovative technologies and received regulatory approvals for their life-saving products. Dexcom's commitment to improving the lives of people with diabetes has earned them a strong reputation in the medical industry. With a dedicated team of professionals, Dexcom continues to make remarkable advancements in CGM technology, offering improved accuracy and user-friendly features to enhance patients' quality of life.
Dexcom Inc has achieved several significant milestones in its corporate history. First, the company introduced the first continuous glucose monitoring (CGM) system, Dexcom STS, which revolutionized diabetes management. They further enhanced the technology with the release of Dexcom Seven Plus CGM system, offering improved accuracy and ease-of-use. Dexcom later introduced the Dexcom G4 Platinum CGM, setting new industry standards with enhanced sensor performance. Another notable milestone was the launch of Dexcom G5 Mobile CGM system, providing real-time glucose monitoring on a mobile device without the need for a separate receiver. These accomplishments reflect Dexcom Inc's commitment to improving the lives of individuals with diabetes through innovative CGM solutions.
Dexcom Inc is primarily present in several countries and regions worldwide. The company operates in the United States, Canada, Europe, including the United Kingdom, Germany, France, Italy, Spain, and Sweden. Dexcom Inc also has a significant presence in Australia and New Zealand, as well as in parts of Asia, such as Japan and South Korea. Additionally, Dexcom Inc has been expanding its reach to other global markets to provide its innovative continuous glucose monitoring systems and diabetes management solutions to a broader customer base.
Dexcom Inc is a reputable company that stands for a set of core values and a strong corporate philosophy. This company believes in providing innovative and life-changing continuous glucose monitoring (CGM) solutions for people with diabetes. Dexcom Inc consistently focuses on delivering accurate and reliable CGM technology, enhancing the lives of individuals managing this chronic condition. With a dedication to improving patient outcomes and quality of life, Dexcom Inc prioritizes patient safety, accessibility, and empowering individuals to make informed decisions about their health. Dexcom Inc's commitment to excellence and patient-centric approach has positioned it as a leader in the field of CGM technology.
Analysts currently set an average price target of 87.74 USD for the Dexcom stock (median: 86.10 USD), implying -0.5 % versus the latest price. The consensus is based on 37 analyst ratings.
37 analysts currently rate the Dexcom stock: 31 recommend buying, 5 holding and 1 selling. For 2026, analysts expect Dexcom to generate revenue of 5.23 B USD and earnings per share of 2.61 USD.
Converted at the current exchange rate, the Dexcom share trades at 75.87 EUR (88.18 USD).
The Dexcom share (DXCM) is listed on 9 stock exchanges, including: NASDAQ (DXCM), XETRA (DC4.DE), Frankfurt (DC4), München (DC4.MU), Düsseldorf (DC4.DU), Hamburg (DC4.HM), London (0A4M.L), SIX (Zürich) (DC4.SW).
Dexcom Inc. is an innovative company in the medical technology industry, specializing in the production of continuous glucose monitoring (CGM) systems for diabetes patients. Dexcom Inc. was founded in 1999 and is headquartered in San Diego, California. Dexcom's core business is the production of CGM systems. These systems allow diabetics to continuously monitor their blood sugar levels without having to regularly take blood samples. Dexcom's CGM systems use tiny sensors that are implanted under the skin to extract glucose levels from tissue. This data is transmitted to a wearable receiver or smartphone, allowing real-time monitoring of glucose levels. Dexcom's CGM systems have been developed for people with type 1 diabetes, type 2 diabetes, and gestational diabetes. In addition to the sensors, Dexcom also offers wearable receivers that allow monitoring of glucose levels at any time and anywhere. Dexcom's systems are FDA certified and have the CE Mark, indicating that they comply with strict safety and efficacy requirements. In addition to its core activity in CGM manufacturing, Dexcom also offers a range of support services for diabetes patients. These include training programs to facilitate the use of CGM systems and a customer support team available 24/7. Furthermore, the company recently entered into a partnership with Apple, allowing the Dexcom app to be downloaded on the Apple Watch, making it even easier to keep track of glucose levels. This collaboration is another step for Dexcom in improving technology and making the use of CGM systems more user-friendly. In terms of its business model, Dexcom earns money through the sale of CGM systems and accessories, as well as by providing support services. The company has an extensive distribution network and is also highly active internationally. Overall, the innovative company Dexcom Inc. has revolutionized the diabetes market with its continuous glucose monitoring. Dexcom Inc. has proven itself as a competent and trustworthy partner for diabetes patients and will continue to make a significant contribution to combating this disease.
The expected revenue of Dexcom is 5.23 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Dexcom is 1.04 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Dexcom is currently 33.81. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Dexcom stock.
The price-to-sales ratio (P/S) of Dexcom is currently 6.73. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Dexcom stock.
The Eulerpool Quality Score for Dexcom is 7/10.
The ISIN of Dexcom is US2521311074. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Dexcom is A0D9T1. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Dexcom is DXCM. The ticker symbol is used to trade Dexcom shares on the stock exchange.
Dexcom paid dividends every year for the past 0 years.
Dexcom is assigned to the 'Health' sector.
The dividends of Dexcom are distributed in USD.
Dexcom stock
Dexcom Peer Group
Dexcom Ticker
Dexcom FIGI
All fundamentals and in-depth analysis of Dexcom
Our stock analysis for Dexcom stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dexcom. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.